Klinische studies radiotherapie-oncologie

Overzicht van lopende klinische studies op onze dienst

Hoofd- en halstumoren

Protocol AG013-ODOM-201: A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically-applied AG013 for the attenuation of oral mucositis in subjects with cancers of the head and neck receiving concomitant chemoradiation therapy.
Study group/sponsor: Oragenics
Contact: Prof. dr. S. Nuyts
Voor meer informatie: https://clinicaltrials.gov/ct2/show/NCT03234465

Protocol EORTC-1420-HNCG-ROG: Phase III study assessing The “best of” radiotherapy compared to the “best of” surgery (trans-oral surgery (TOS)) in patients with T1-T2, N0 oropharyngeal carcinoma.
Study group/sponsor: EORTC
Contact: Prof. dr. S. Nuyts
Voor meer informatie: https://clinicaltrials.gov/ct2/show/NCT02984410

Protocol: A two-arm phase II randomized study comparing 18F-FDG-PET-CT based dose escalation versus standard radiotherapy in high risk head and neck squamous cell carcinoma
Contact: Prof. dr. S. Nuyts

Protocol: Combined hypofractionated stereotactic body radiotherapy with immunomodulating systemic therapy for inoperable recurrent head and neck cancer: detection of the maximum tolerated dose.
Contact: Prof. dr. S. Nuyts
Voor meer informatie: https://clinicaltrials.gov/ct2/show/NCT03402737

Protocol: Prediction of outcome after chemoradiotherapy for head and neck cancer using functional imaging and tumor biology.
Contact: Prof. dr. S. Nuyts
Voor meer informatie: https://clinicaltrials.gov/ct2/show/NCT01829646

Protocol: Towards a patient supported, well tolerated and evidence based prophylactic swallowing exercise program to improve quality of life and swallowing function in head and neck cancer patients treated with chemoradiotherapy – a multicenter randomized trial.
Contact: Prof. dr. S. Nuyts

Gastro-intestinale tumoren

EORTC 22114-40111/TopGear: A randomised Phase II/III Trial of Preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer.
Study group/sponsor: EORTC.
Contact: Prof. dr. K. Haustermans.
Voor meer informatie: www.eortc.org/clinical-trials

Protocol: EUS-guided fiducial marker placement in patients with esophageal cancer
Contact: Prof. dr. K. Haustermans.

Protocol: Novel strategies for organ-sparing in rectal cancer patients with complete response to radiochemotherapy. (s58706)
Contact: Prof. dr. K. Haustermans.

Prostaatkanker

Protocol EORTC 1531-ROG: Radiotherapy and 6-month androgen deprivation therapy with or without Apalutamide in Intermediate and Limited High Risk Localized Prostate Cancer: a phase III study.
Study group/sponsor: EORTC
Contact: Prof. dr. K. Haustermans
Voor meer informatie: https://clinicaltrials.gov/ct2/show/NCT03488810

Protocol: PART: Elective Para-Aortic Radiotherapy (PART) for pN1 prostate cancer: a phase 2 trial using Arc Therapy (IMAT / VMAT).
Contact: Prof. dr. G. De Meerleer
Voor meer informatie: https://clinicaltrials.gov/ct2/show/NCT03079323

Cervixtumoren

Embrace: A European study on MRI-guided brachytherapy in locally advanced cervical cancer.
Study group/sponsor: Medical University Vienna.
Contact Prof. E. Van Limbergen.
Voor meer informatie: clinicaltrials.gov/ct2/show/NCT00920920

Hersentumoren

Protocol EORTC 26053: phase III trial on concurrent and adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma (EORTC 26053). Temozolomide is an alkylating agent.
Study group/sponsor: EORTC.
Contact Prof. J. Menten (in samenwerking met Prof. P. Clement).
Voor meer informatie: www.cancertrials.be

Longkanker

Prophylactic Cranial Irradiation with or without hippocampal avoidance in SCLC: a randomized phase III study.
Study group/sponsor: NKI/AVL Amsterdam.
Contact Prof. D. De Ruysscher.
Voor meer informatie: clinicaltrials.gov/ct2/show/NCT01780675

PET Boost: Dose-escalation by boosting radiation dose within the primary tumor on the basis of a pre-treatment FDG-PET-CT scan in stage IB, II and III NSCLC: A randomized phase II trial.
Study group/sponsor: NKI/AVL Amsterdam.
Contact Prof. D. De Ruysscher.
Voor meer informatie: clinicaltrials.gov/ct2/show/NCT01024829

Laatste aanpassing: 24 januari 2020